May 10, 2019
The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.
January 14, 2019
In 2018 we have seen increased investments in Alzheimer's biomarkers and increased interest in prevention.
January 11, 2019
The Alzheimer's Drug Discovery Foundation awarded new funding to studies that focus on prevention.
January 9, 2019
A review by the ADDF published in Neurology® explores novel approaches beyond the common amyloid that could slow or prevent Alzheimer's.
September 24, 2018
Researchers shared updates on their approaches to developing Alzheimer's treatments at our annual conference.
September 17, 2018
Michele Gallagher, PhD, is the recipient of the fourth Melvin R. Goodes Prize, which includes a $150,000 award to support the therapeutic development of AGB-101.
September 13, 2018
The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.
July 13, 2018
The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.
May 10, 2018
We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease.
May 4, 2018
Learn about clinical trials, an important and growing part of our funding at the Alzheimer’s Drug Discovery Foundation.